+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Biopharmaceutical CMO & CRO Market by Source, Service Type, Product, Scale of Operation, Therapeutic Applications - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010880
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Biopharmaceutical CMO & CRO Market grew from USD 81.32 billion in 2023 to USD 95.65 billion in 2024. It is expected to continue growing at a CAGR of 18.10%, reaching USD 260.65 billion by 2030.

The Biopharmaceutical Contract Manufacturing Organizations (CMO) and Contract Research Organizations (CRO) market is an integral part of the pharmaceutical industry, supporting companies in research, development, and manufacturing processes. This market addresses the growing demand for cost-efficient methods to bring complex biopharmaceutical products to market faster. Its necessity stems from the increasing need for flexibility, expertise, and global reach in drug development and manufacturing processes. The primary application involves outsourcing specialized services, including clinical trials, regulatory compliance, and large-scale biologics production. End-users primarily include large pharmaceutical companies and emerging biotech firms seeking to streamline operations and reduce overhead. Key growth factors in this market include the rise of biologics and biosimilars, increasing R&D activities, and expanding pipelines across therapeutic areas like oncology and infectious diseases. Further opportunities arise from advancements in cell and gene therapies, personalized medicine, and technological innovations such as single-use technologies and automation. To leverage these opportunities, companies should focus on strategic partnerships, enhance service offerings with innovative bioprocessing technologies, and maintain regulatory compliance. However, market growth faces challenges like stringent regulatory environments, high competition, and complex logistical demands of sophisticated biologics production. In terms of innovation, investing in digital solutions like artificial intelligence and data analytics can optimize operations and improve decision-making processes. Developing expertise in emerging therapies and expanding capabilities in fast-evolving sectors like precision medicine could position firms for growth. Overall, the biopharmaceutical CMO and CRO market is dynamic and competitive, driven by technological advancements and the growing demand for specialized services. Companies that can navigate these challenges while investing in cutting-edge technologies and strategic collaborations are well-positioned to thrive.

Understanding Market Dynamics in the Biopharmaceutical CMO & CRO Market

The Biopharmaceutical CMO & CRO Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising need for outsourced service in pharmaceutical and biotechnology sector
    • Potential demand for macromolecular therapeutics
    • Ongoing research and development activities in biopharmaceutical sector
  • Market Restraints
    • Issues pertinent to fewer outsource suppliers and less competition
  • Market Opportunities
    • Penetration of advanced technology in the biotechnology field
    • Emergence of Cell and Gene Therapies for Targeted Treatment
  • Market Challenges
    • Concern associated with accountability and quality control of CMO and CRO

Exploring Porter’s Five Forces for the Biopharmaceutical CMO & CRO Market

Porter’s Five Forces framework further strengthens the insights of the Biopharmaceutical CMO & CRO Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Biopharmaceutical CMO & CRO Market

External macro-environmental factors deeply influence the performance of the Biopharmaceutical CMO & CRO Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Biopharmaceutical CMO & CRO Market

The Biopharmaceutical CMO & CRO Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Biopharmaceutical CMO & CRO Market

The Biopharmaceutical CMO & CRO Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Biopharmaceutical CMO & CRO Market

The Biopharmaceutical CMO & CRO Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceutical CMO & CRO Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., arexel International Corporation, Baxter International Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific Limited, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON Plc, KBI Biopharma, Inc., KEMWELL BIOPHARMA PRIVATE LIMITED, Laboratory Corporation of America Holdings, Lonza Group AG, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Patheon Inc., Rentschler Biopharma SE, and Sterling Pharma Solutions.

Market Segmentation & Coverage

This research report categorizes the Biopharmaceutical CMO & CRO Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Source
    • Mammalian
    • Non-Mammalian
  • Service Type
    • Contract Manufacturing
    • Contract Research
  • Product
    • Biologics
    • Biosimilars
  • Scale of Operation
    • Clinical
    • Commercial
  • Therapeutic Applications
    • Cardiovascular Diseases
    • Infectious Disease
    • Neurology
    • Oncology
    • Ophthalmology
    • Respiratory Disorder
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising need for outsourced service in pharmaceutical and biotechnology sector
5.1.1.2. Potential demand for macromolecular therapeutics
5.1.1.3. Ongoing research and development activities in biopharmaceutical sector
5.1.2. Restraints
5.1.2.1. Issues pertinent to fewer outsource suppliers and less competition
5.1.3. Opportunities
5.1.3.1. Penetration of advanced technology in the biotechnology field
5.1.3.2. Emergence of Cell and Gene Therapies for Targeted Treatment
5.1.4. Challenges
5.1.4.1. Concern associated with accountability and quality control of CMO and CRO
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Biopharmaceutical CMO & CRO Market, by Source
6.1. Introduction
6.2. Mammalian
6.3. Non-Mammalian
7. Biopharmaceutical CMO & CRO Market, by Service Type
7.1. Introduction
7.2. Contract Manufacturing
7.3. Contract Research
8. Biopharmaceutical CMO & CRO Market, by Product
8.1. Introduction
8.2. Biologics
8.3. Biosimilars
9. Biopharmaceutical CMO & CRO Market, by Scale of Operation
9.1. Introduction
9.2. Clinical
9.3. Commercial
10. Biopharmaceutical CMO & CRO Market, by Therapeutic Applications
10.1. Introduction
10.2. Cardiovascular Diseases
10.3. Infectious Disease
10.4. Neurology
10.5. Oncology
10.6. Ophthalmology
10.7. Respiratory Disorder
11. Americas Biopharmaceutical CMO & CRO Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Biopharmaceutical CMO & CRO Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Biopharmaceutical CMO & CRO Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BIOPHARMACEUTICAL CMO & CRO MARKET RESEARCH PROCESS
FIGURE 2. BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BIOPHARMACEUTICAL CMO & CRO MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIOPHARMACEUTICAL CMO & CRO MARKET DYNAMICS
TABLE 7. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CONTRACT RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY RESPIRATORY DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 42. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 43. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 45. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 46. CANADA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 47. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 51. MEXICO BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 69. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 70. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 71. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 72. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 73. CHINA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 74. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 75. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 77. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 78. INDIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 84. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 85. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 86. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 87. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 88. JAPAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 114. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 115. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 116. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 117. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 118. THAILAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 130. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 131. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 132. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 133. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 134. DENMARK BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 135. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 136. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 137. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 138. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 139. EGYPT BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 140. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 141. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 142. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 143. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 144. FINLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 148. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 149. FRANCE BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 153. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 154. GERMANY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 160. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 161. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 162. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 163. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 175. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 176. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 177. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 178. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 179. NORWAY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 180. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 181. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 182. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 183. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 184. POLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 185. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 186. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 188. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 189. QATAR BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 205. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 206. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 208. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 209. SPAIN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 220. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 221. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 223. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 224. TURKEY BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM BIOPHARMACEUTICAL CMO & CRO MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 235. BIOPHARMACEUTICAL CMO & CRO MARKET SHARE, BY KEY PLAYER, 2023
TABLE 236. BIOPHARMACEUTICAL CMO & CRO MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Biopharmaceutical CMO & CRO market, which are profiled in this report, include:
  • AbbVie, Inc.
  • arexel International Corporation
  • Baxter International Inc.
  • Boehringer Ingelheim Biopharmaceuticals GmbH
  • Boehringer Ingelheim GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific Limited
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • ICON Plc
  • KBI Biopharma, Inc.
  • KEMWELL BIOPHARMA PRIVATE LIMITED
  • Laboratory Corporation of America Holdings
  • Lonza Group AG
  • NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
  • Patheon Inc.
  • Rentschler Biopharma SE
  • Sterling Pharma Solutions

Methodology

Loading
LOADING...

Table Information